Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the best drug stocks to buy according to analysts. On April 7, RBC ...

GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...

Six biotechs based in California, Massachusetts, Washington and Denmark had to halt drug development efforts this year. One ...

Altitude Labs, an offshoot of AI-focused techbio Recursion, is teaching scientists to build companies, one founder at a time.

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...

Myelofibrosis drug developer Syntara is the latest biotech to tap the market in a lively climate for capital raisings.

Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...

Fermentation has evolved from a traditional preservation method into a cornerstone of modern food innovation, where the intersection of bioprocess ...

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.

Panchkula, Rajeev Goyal had on April 20 discharged Parmar, Roop Bansal of the M3M, Lalit Goyal of the IREO, Anil Bhalla of the Vatika Group and Ajay Parmar, the nephew of the suspended judicial office ...

In its SEC prospectus, Hemab says it intends to use the net proceeds, together with existing cash, to fund clinical ...